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Abstract: Extended thromboprophylaxis given to medically ill patients for up to 45 days following
an acute hospitalization remains an emerging topic among many hospital-based health care providers.
Recent advancements in the field of extended thromboprophylaxis using risk stratification and
careful patient selection criteria have led to an improved safety profile of direct oral anticoagulants
(DOACs) and established net clinical benefit when given to key patient subgroups at high risk of
venous thromboembolism (VTE) and low risk of bleeding. The Food and Drug Administration
(FDA) has now approved the DOACs betrixaban and rivaroxaban for both in-hospital and extended
thromboprophylaxis in medically ill patients in these key subgroups, which represents more than
one-quarter of hospitalized medically ill patients. This has potential to significantly reduce VTE-related
morbidity and mortality for these patients. Emerging data also supports reductions in the risk of
arterial thromboembolism in medically ill patients with extended thromboprophylaxis post-hospital
discharge using DOACs. This article aims to review the most recent concepts of predicting and
preventing VTE and to discuss emerging paradigms of extended thromboprophylaxis in hospitalized
medically ill patients utilizing an individualized, risk-adapted approach.
Keywords: venous thromboembolism; medically ill patients; direct oral anticoagulants;
extended thromboprophylaxis
1. Introduction
A significant proportion of the estimated 20 million hospitalized, acutely-ill medically-ill patients in
the USA and EU are at risk of developing venous thromboembolism (VTE) [1,2]. Prophylactic treatments
with unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and the pentassacharide
fondaparinux have shown a 50%–60% reduction in total VTE given for 6–14 days [3–5]. However,
hospital length-of-stay (LOS) in the USA now averages approximately 4.5 days and is decreasing in
Canada and the European Union [6]. Despite consistent data that show more than 60% of all VTEs
occur after the post-hospital discharge period and that the majority of VTE events (approximately 80%)
occur within 6 weeks after discharge, post-hospital thromboprophylaxis is given to less than 4% of
hospitalized medically-ill patients [7,8].
Until recently, the topic of extended thromboprophylaxis with direct oral anticoagulants (DOACs)
for up to 45 days in hospitalized medically ill patients has been a controversial one. At least 25%
of all medically ill patients are at sufficient VTE risk to benefit from extended thromboprophylaxis,
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but earlier placebo-controlled randomized trials with enoxaparin, and the DOACs rivaroxaban and
apixaban, failed to establish a definitive net clinical benefit in overall populations due to an increase in
bleeding [9–11]. Data from meta-analyses supported an approximate 40% decrease in symptomatic
VTE and VTE-related death with extended thromboprophylaxis, but at a cost of a two-fold increase
in major bleeding (MB) [12]. Antithrombotic guidelines for the overall population of medically ill
patients have recommended against routine use of extended thromboprophylaxis with DOACs without
reference to specific subgroups that may benefit from such a strategy, with the exception of one
guideline (International Union of Angiology) that recommended an individualized approach for
extended thromboprophylaxis [13–15].
There have been recent developments and new data in the field of extended thromboprophylaxis
in medically ill patients that have led to an improved safety profile of DOACs and the establishment of
net clinical benefit in key patient subgroups. These developments led to recent FDA approvals of both
betrixaban and rivaroxaban for both in-hospital and extended thromboprophylaxis in key subgroups of
medically ill patients [16,17]. These approvals have potential in preventing both VTE-related morbidity
and mortality and associated risks of arterial thromboembolism in this population [18–20]. This article
aims to review the most recent concepts of predicting and preventing VTE and to discuss emerging
paradigms of extended thromboprophylaxis in key patient subgroups of hospitalized medically ill
patients utilizing an individualized, risk-adapted approach.
2. Extended Thromboprophylaxis during the Post-Hospital Discharge Period
While most VTE-prevention efforts in hospitalized medically-ill patients have been directed
towards the period of acute hospitalization, studies now show that at least 60% of all VTE events occur
in the post-hospital discharge period [8,21]. During the first 21-days following discharge, the rate of
symptomatic VTE more than doubles and there is an associated 5-fold increase in fatal pulmonary
embolism (PE) within 45 days [21]. Despite this being a high-risk period with significant health
consequences, the benefits of extended duration thromboprophylaxis remained uncertain among
hospital-based health care providers, as reflected in antithrombotic guidelines [13,15]. There have been
five studies on extended thromboprophylaxis in medically ill patients four studies comparing extended
prophylaxis with enoxaparin 40 mg daily, apixaban 2.5 mg twice daily, rivaroxaban 10 mg daily,
and betrixaban 80 mg daily, to standard of care enoxaparin 40 mg daily given for 6 to 14 days that used
screening ultrasonography of the lower limbs to assess deep venous thrombosis (DVT) [9–11,18,19],
and one study comparing extended thromboprophylaxis with rivaroxaban post hospital discharge with
placebo that used symptomatic VTE and VTE-related mortality as the primary efficacy endpoint [19].
The results of these studies were mixed.
The Extended Prophylaxis for Venous Thromboembolism in Acutely Ill Medical Patients with
Prolonged Immobilization trial (EXCLAIM trial) revealed a net clinical benefit with the use of
extended-duration enoxaparin in patients with severe immobility, age older than 75 years, and female
sex, but only after a major protocol amendment during the study which rendered the results difficult to
interpret [9]. In the Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients trial
(ADOPT trial), an overall low VTE risk population was identified, and apixaban failed to show efficacy
and was associated with significantly more MB events [10]. The Rivaroxaban for Thromboprophylaxis
in Acutely Ill Medical Patients trial (MAGELLAN trial) identified a higher VTE risk population and
saw a significant reduction in VTE risk with extended-duration rivaroxaban compared to enoxaparin
(Relative Risk (RR) 0.77; 95% CI 0.62–0.96) but was associated with an almost 3-fold increase in the risk
of MB, including a numerically greater number of fatal bleeds [11]. The Extended Thromboprophylaxis
with Betrixaban in Acutely Ill Medical Patients trial (APEX trial) with the DOAC betrixaban also
identified a high VTE risk population and narrowly failed to show efficacy in the primary efficacy
outcome utilizing a defined patient subgroup, but a pre-specified exploratory analysis provided
evidence suggesting a benefit for betrixaban in the total population (RR 0.76; 95% CI 0.63–0.97) [18].
Importantly there was no increase in the risk of MB (0.57% vs. 0.67%, p = 0.55), although there
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was an increase in major or clinically-relevant non-major bleeding (3.1% vs. 1.6%, p < 0.001) [18].
A bivariate analysis of this trial revealed a net clinical benefit of −0.51% (95% CI −0.89% to −0.1%)
over enoxaparin [22]. The Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical
Illness trial (MARINER trial) failed to meet its primary efficacy endpoint but revealed significant
reductions in the pre-specified secondary outcomes of symptomatic non-fatal VTE (Hazards Ratio
(HR) 0.44; 95% CI 0.22–0.89) and symptomatic VTE and all-cause mortality (HR 0.73, 95% CI 0.54–0.97,
p = 0.033) [19]. The incidence of MB in both groups was very low (0.28% vs. 0.15, HR 1.88; 95% CI
0.84–4.23), although there was an increase in clinically relevant non-major bleeding (1.42% vs. 0.85%,
HR 1.66; 95% CI 1.17–2.35) [19]. Furthermore, the primary efficacy endpoint was met in a sub-group
of patients given a 3–6-day course of rivaroxaban (HR 0.55; 95% CI 0.31–0.97), which reflects current
LOS in USA hospitals [6,19]. Importantly, a post-hoc analysis of the MAGELLAN trial that excluded
approximately 20% of the study population by removing the five key bleeding risk factors used to
identify a low bleed risk population in the MARINER trial (bronchiectasis/pulmonary cavitation,
active cancer, active gastroduodenal ulcer/history of bleeding within 3 months, and dual antiplatelet
therapy) maintained the efficacy of rivaroxaban but reduced the major bleed rates by half so that MB
was not significantly worse with rivaroxaban (Day 10, RR 1.19, 95% CI 0.54–2.65; Day 35 RR 1.48, 95% CI
0.77–2.84), in addition to dramatically reducing the rates of fatal bleeding in both treatment phases [20].
Based on a favorable net clinical benefit found in the modified intent-to-treat population in
the APEX trial of which there was an evaluable efficacy outcome event, as well as a favorable net
clinical benefit in the MAGELLAN subpopulation in which the high bleed risk subgroup with five
key bleed risk factors was removed, the FDA has approved both betrixaban 160 mg per os (PO)
followed by 80 mg PO daily and more recently rivaroxaban 10 mg PO daily for both inpatient as
well as extended post-hospital discharge thromboprophylaxis (31 days up to 39 days) in hospitalized
medically ill patients [16,17]. Patients included in these trials were ≥40 years with an acute medical
illness, immobility, and had added VTE risk factors.
3. Predicting High VTE Risk Medically Ill Patients and Use of Risk Assessment Models
Recent studies have identified key VTE risk factors that place medically ill patients at high
risk for VTE post-hospital discharge, and therefore, are more likely to benefit from extended
thromboprophylaxis, as shown in Table 1. These key VTE risk factors have either been incorporated
individually, as seen in the MAGELLAN and APEX trials, or used as part of a scored and weighted
VTE risk assessment model (RAM), such as the modified International Medical Prevention Registry
on Venous Thromboembolism (IMPROVE) VTE RAM, as used in the MARINER trial (Table 2).
This validated, evidence-derived RAM is a tool that can help guide physicians in the decision-making
process of assessing an individual’s VTE risk. The MAGELLAN trial included added VTE risk
factors such as age ≥ 75 years, severe varicosities, chronic venous insufficiency, history of malignancy,
history of DVT/PE, history of heart failure, thrombophilia, recent major surgery or serious trauma,
the use of hormone replacement therapy, BMI ≥ 35 kg/m2, and acute infectious disease contributing
to hospitalization [11]. A post-hoc analysis also identified an elevated D-dimer (Dd) > 2 times the
upper limit of normal as an additive VTE risk factor [23]. The APEX trial included age ≥ 75 years,
a history of cancer or VTE, and an elevated Dd as key additive VTE risk factors [18]. A post-hoc
analysis of the APEX trial using a modified IMPROVE VTE RAM that incorporated a score of 2
for elevated Dd (the IMPROVEDD VTE RAM) also identified a population with a >2 fold higher
VTE risk (HR 2.74, 95% CI 1.52–4.90) than those with a score of 0–1 [24]. The MARINER trial used
a modified IMPROVE VTE score of ≥4 or a score of 2 or 3 with elevated Dd as part of the inclusionary
criteria, although the observed VTE incidence in the placebo group (1.1%) was lower than the expected
incidence of 2.0%–2.5% [19]. Lastly, a recent sub-analysis of the MAGELLAN database also established
that the modified IMPROVE VTE RAM with a cut-off score of ≥4 or a score of 2 or 3 with elevated Dd
(as used in the MARINER trial) identified a nearly 3-fold higher VTE risk subpopulation of patients
with a significant benefit for extended thromboprophylaxis [25]. The totality of evidence from clinical
J. Clin. Med. 2020, 9, 1002 4 of 10
trials, systematic reviews, and a recent meta-analysis on the subject suggests that key VTE risk factors
such as previous history of VTE, cancer, known thrombophilia, elevated Dd, advanced age, critical
illness, infections, and severe immobility or lower extremity paresis, either as independent risk factors
or as part of a VTE RAM, such as IMPROVE, predict a high VTE risk population that would benefit
from extended thromboprophylaxis [22,26]. With respect to severe immobility, there have been various
definitions that have focused either on the nature or duration of immobility, including the inability
to sustain autonomous walking or greater than 10 m and total bedrest with and without bathroom
privileges, although more recent definitions have tied severe immobility to the disease state and initial
hospitalization period [27,28].
Table 1. Established individual or model-based venous thromboembolism (VTE) risk factors in
hospitalized medically ill patients for extended thromboprophylaxis (factors in bold have more
consistently shown high VTE risk in the post-discharge period).
Individual High VTE Risk Factors Points for the Risk Factor
History of VTE Padua—3 points; IMPROVE—3 points
Known thrombophilia Padua—3 points; IMPROVE—2 points *
Family history of VTE
Acute infection Padua—1 point
Malignancy Padua—3 points; IMPROVE—2 points **
Advanced Age Padua—1 point; IMPROVE—1 point ***
Severe varicosity/venous insufficiency
Use of hormone replacement therapy Padua—1 point
Recent trauma or surgery Padua—1 point
Morbid obesity Padua—1 point ****
Congestive heart failure Padua—1 point
Stroke with or without Paresis Padua—1 point; IMPROVE—2 points *****
Immobility or Reduced Mobility Padua—3 points; IMPROVE—1 point ******
Pregnancy/postpartum
Acute/chronic lung disease or respiratory failure Padua—1 point
Acute inflamatory disease or rheumatologic disorder Padua—1 point
Shock/ICU/CCU stay IMPROVE—1 point
Elevated Dd (>2 × ULN) IMPROVEDD—2 points
VTE Risk Assessment Models (RAMs) for high VTE risk: Padua VTE risk score of 4 or more; IMPROVE VTE risk
score of 4 or more or score of 2 or 3 with elevated Dd; IMPROVEDD VTE risk score of 2 or more *******. * A congenital
or acquired condition leading to excess risk of thrombosis (e.g., factor V Leiden, lupus anticoagulant, factor C or
factor S deficiency). ** May include active cancer (excluding non-melanoma skin cancer) or a history of cancer within
5 years. *** Padua score age > 70 years, IMPROVE score age > 60 years. **** Padua score body mass index (BMI)
> 30. ***** IMPROVE score with lower limb paralysis (leg falls to bed by 5 s, but has some effort against gravity,
taken from NIH stroke scale). ****** The IMPROVE score’s strict definition is complete immobilization confined
to bed or chair ≥ 7 days; the modified definition is complete immobilization ≥ 1 day. ******* The IMPROVEDD
VTE score has not undergone external validation. VTE, venous thromboembolism; ICU, intensive care unit; CCU,
cardiac care unit; Dd, d-dimer; ULN, upper limit of normal; IMPROVE, International Medical Prevention Registry
on Venous Thromboembolism.
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Table 2. The IMPROVE VTE RAM *.
VTE Risk Factor Points for the Risk Score
Previous VTE 3
Thrombophilia ** 2




Age > 60 years 1
Abbreviations: IMPROVE, International Medical Prevention Registry on Venous Thromboembolism; VTE, venous
thromboembolism; RAM, risk assessment model; ICU, intensive care unit; CCU, coronary care unit. * A score of 0–1
constitutes low VTE risk; a score of 2–3 constitutes moderate VTE risk; a score of 4 or more constitutes high VTE risk.
** A congenital or acquired condition leading to an excess risk of thrombosis. *** Leg falls to bed by 5 s, but has
some effort against gravity (from NIH stroke scale). **** May include active cancer (excluding non-melanoma skin
cancer) or a history of cancer within 5 years. ***** Strict definition is complete immobilization confined to bed or
chair ≥7 days; modified definition is complete immobilization with or without bathroom privileges ≥1 day.
4. The Use of Health Informatics Technology and VTE Risk Assessment
Recent efforts have been made to increase the rate of appropriate thromboprophylaxis in medically
ill patients by integrating VTE RAMs into each hospital’s electronic medical record (EMR). Informatics
technologies such as “Substitutable Medical Applications, Reusable Technologies SMART on Fast
Healthcare Interoperability Resource (FHIR) [29],” now have the potential to tie VTE RAMs to
an electronic order entry within the workflow of any EMR and alert physician of a patient’s
individualized VTE risk. Randomized trials have shown that the use of these electronic alerts has
more than doubled the prescription of thromboprophylaxis compared to standard medical care [30–32].
This has been shown to be true during both hospital admission for in-hospital thromboprophylaxis
and at hospital discharge for extended thromboprophylaxis [30–32]. In addition to doubling the
rate of pharmacologic prophylaxis with computer alerts (23.6% versus 13%, p < 0.001), one study
revealed a significant 41% reduction in the incidence of VTE at 90 days (HR 0.59, 95% CI 0.43–0.81,
p = 0.001) [30]. Another study revealed a significant increase in the rate of thromboprophylaxis with
the use of discharge alerts (22% versus 9.7%, p < 0.0001); however, there was no difference in the
rate of symptomatic VTE at 90 days (4.5% versus 4.0%, HR 1.12, 95% CI 0.74–1.69) [32]. This study
did not mandate a specific recommendation for post-hospital discharge thromboprophylaxis tied to
a discharge alert, highlighting the fact that computer alerts need to be associated with an actionable
outcome such as order entry for them to be effective. While it has been shown that health informatics
technology has potential to alter provider behaviors, further study as to whether this technology alters
clinical outcomes is warranted.
5. Controversies in Antithrombotic Guidelines for Medically Ill Patients
The 2018 American Society of Hematology Guidelines provide a strong recommendation for the
use of thromboprophylaxis with LMWH only during the period of acute hospitalization, rather than
with a DOAC during both acute hospitalization and post-hospital discharge [15]. Furthermore, while
forming the basis of these guidelines, the original study endpoint of total VTE was not utilized,
which included asymptomatic proximal DVT [15]. It has been consistently shown that a significant
association exists between asymptomatic proximal DVT found on screening ultrasonography and
an increased risk of all-cause mortality, an association that does not exist with other endpoints such as
asymptomatic distal DVT or clinically relevant non-major bleeding [33–35]. Therefore, by not including
this key primary efficacy endpoint used in the original clinical trials, the guidelines failed to capture
the true risk of total VTE and potentially expose high-VTE risk patients to the risks and consequences
of VTE in the absence of thromboprophylaxis. These guidelines also failed to establish whether there
was net clinical benefit in favor of extended thromboprophylaxis in low bleed risk patient subgroups,
as seen in the MAGELLAN subgroup, APEX, and MARINER trials. A more appropriate interpretation
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of the data—in light of a clear establishment of net clinical benefit and subsequent regulatory approval
of both betrixaban and rivaroxaban for extended thromboprophylaxis in key patient subgroups at high
VTE and low bleed risk, would be to recommend an individualized, risk-adapted approach to predict
which medically-ill patients would benefit the most from post-discharge extended thromboprophylaxis
and recommend treatment accordingly. We have included such an evidence-derived algorithm in
Figure 1.
Figure 1. VTE risk assessment and thromboprophylactic strategies for hospitalized medically ill patients
prior to discharge. * High VTE risk factors: history of VTE, advanced age, cancer (either active cancer
excluding non-melanoma skin cancer or history of cancer within 5 years), severe immobility, stroke with
paresis, known thrombophilia, elevated Dd. ** Requires external validation. IMPROVE, International
Medical Prevention Registry on Venous Thromboembolism; VTE, venous thromboembolism; UFH,
unfractionated heparin; IU, international units; SQ, subcutaneously; BID, twice a day; TID, three times
a day; QD, once a day; PO, per os.
6. Arterial Thromboembolism and Extended Thromboprophylaxis in the Medically Ill
While an association between VTE and atherosclerosis has been known to exist for some time [36],
less is known about the use of extended thromboprophylaxis for the prevention of arterial events,
such as myocardial infarction, cardiopulmonary death, and ischemic stroke. Post-hoc analyses of
the APEX study revealed that extended thromboprophylaxis with betrixaban significantly reduced
all-cause stroke (0.54% versus 0.97%; RR 0.56; 95% CI 0.32–0.96; number needed to treat (NNT) 233)
and ischemic stroke (0.48% versus 0.91%; RR 0.53; 95% CI 0.30–0.94; NNT 233) through 77 days of
follow-up [37], in addition to significantly reducing irreversible and fatal thromboembolic events
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(cardiopulmonary death, myocardial infarction, pulmonary embolism, and ischemic stroke) in all
patients at 35 to 45 days (4.08% versus 2.90%; HR 0.71; p = 0.006; NNT 86), and 77 days (5.17%
versus 3.64%; HR 0.70; p = 0.002; NNT 65) compared to standard duration thromboprophylaxis [38].
A pre-specified analysis of the MARINER study revealed extended thromboprophylaxis, with the
10 mg dose of rivaroxaban having significantly reduced major and fatal thromboembolic events
(including symptomatic VTE, myocardial infarction, ischemic stroke, and cardiovascular death) at
45 days (1.28% versus 1.77%, HR 0.72, 95% CI 0.52–1.00, p = 0.049, NNT 204) without an increased
risk of MB [39]. Finally, pooled analysis of the MAGELLAN and MARINER trials for extended
thromboprophylaxis with rivaroxaban revealed a significant reduction (2.31% versus 1.70%, HR 0.78,
NNT 197) in major thromboembolic events and all-cause mortality without an increased risk of critical
site/fatal bleeding [40]. The ability for extended duration thromboprophylaxis to prevent irreversible
and fatal arterial thromboembolic events is a new area of research that requires further investigation.
7. Populational Implications and Future Outlook for Extended Thromboprophylaxis in the
Medically Ill
Despite FDA approvals of two DOACs and major populational health consequences of
withholding extended thromboprophylaxis in appropriate patients, extended thromboprophylaxis
remains an evolving field among regulatory bodies, as The European Medicines Agency
(EMA) has rejected betrixaban for this purpose and rivaroxaban is currently under review [41].
Extended thromboprophylaxis in medically ill patients represents a new paradigm for health
care professionals as well. Evidence suggests that approximately 25% (and up to 40%) of the
7.2 million medically ill patients in the USA would benefit from extended thromboprophylaxis [42,43].
Applying reductions in symptomatic VTE seen in the APEX trial with betrixaban would result in
~20,000 fewer symptomatic VTEs and the potential to result in 12,000 fewer VTE-related deaths [44].
Data based on the MAGELLAN subgroup suggests that in the EU and USA health systems, a strategy
of extended thromboprophylaxis with rivaroxaban has the potential to prevent symptomatic VTE and
VTE-related death in approximately 24,000 patients annually at the cost of one half to one fourth that
number (approximately 6000 to 12,000 patients) in MB or fatal bleeding events [20]. The advent of
oral options for thromboprophylaxis of medically ill patients for both the in-hospital and extended
post-hospital discharge period, represents a major advancement in the field of thrombosis, and has the
potential to improve patient adherence and patient outcomes [45]. Health informatics technologies
are now able to tie VTE RAMs to an electronic order entry within the workflow of any EMR and
have potential to reduce the morbidity and mortality associated with hospital-acquired VTE, both
in-hospital and in the post-hospital discharge period. The field of extended thromboprophylaxis in the
large population of medically ill patients is rapidly evolving, and there is an urgent need to update
antithrombotic guidelines based on the best available evidence in order to improve adverse outcomes
associated with VTE and minimize harm from chemoprophylactic strategies in appropriately defined
patient groups.
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